Authors
Rui-Jin Jiang, Dong-Lou Wang, Xiao-Mei Yan, Dao-Sheng Xue, Jia-Hao Gu, Xiao-Xu Bi, Yong-Ming Yan, Ying Wang, Xue-Mei Niu, Jiang-Bo He
Published in
Journal of natural products. Volume 89. Issue 9. Pages 2582-2602. Sep 25, 2026.
Abstract
Engineered Aspergillus oryzae strains possessing four biosynthetic genes (AOL_s00215g276-279) from carnivorous fungus Arthrobotrys oligospora enabled the isolation of 17 toluquinol-derived meroterpenoids. Thirteen were previously undescribed, including (±)-spinulinoid G (1a/1b), (±)-kuhistanol H (2a/2b), (±)-anthoponoid J (3a/3b), (±)-anthoponoid K (4a/4b), (+)-nitrosporeunol E (5a), (E)-2-methyl-3'-methoxyfarnesyl toluquinol (6), methylfarnesylquinone B (7), methylfarnesylquinone C (8), and didehydroconicol B (9), along with four known analogues (5b, 10-12). Their structures were elucidated by extensive spectroscopic analyses, and the absolute configurations were assigned by TDDFT-ECD calculations and/or comparison of optical rotation data with those of structurally related compounds. Several compounds (2a, 2b, 4a, 10, and 12) exhibited cytotoxic activity against human cancer cell lines BGC803, HCT116, MIA PaCa-2, and HeLa. Compound 2b showed prominent cytotoxicity against HCT116 and HeLa cells, with IC50 values of 7.69 μM and 5.60 μM, respectively. Furthermore, network pharmacology highlighted compounds 2b and 4a and suggested HIF1A and PIK3CA as candidate targets, for which molecular docking predicted plausible binding modes. These findings expand meroterpenoid structural diversity and provide promising small-molecule scaffolds for anticancer lead development.
PMID:
42913382
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0